Ian Quirk

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Barts & The London NHS Trust provides health care services in hospitals. Its services include air ambulance, hepatology, anaesthetics and pain management, haematology, paediatric respiratory, emergency department, endocrinology, Urology, and many more. The company is headquartered in Aldgate, the United Kingdom.

Vascular Flow Technologies Ltd. develops vascular devices. It offers Spiral Flow Peripheral Vascular Graft, Spiral Flow AV Access Graft, Spiral Laminar Flow, Power of Spiral Laminar Flow and unique design eliminates graft turbulences. The company was founded by Peter Stonebridge, Brian Howlett, Graeme Houston and John B.C. Dick and headquartered in Dundee, the United Kingdom.

Otivio AS manufactures non-invasive medical devices. The private company is based in Oslo, Norway.

SurgaColl Technologies Ltd. manufactures medical devices. It supplies novel tissue regeneration products for the surgical treatment of disease of the bone, cartilage, and other human tissue. The firms products include HydroxyColl and ChondroColl. The company was founded by John Gleeson, Pat Forristal, Fergal O'Brien, and Dann Philpott on November 22, 2010 and is headquartered in Glasnevin, Ireland.

Lightpoint Medical Ltd. develops imaging technology for cancer surgery. It has developed a groundbreaking surgical imaging technology based on Cerenkov Luminescence Imaging(CLI). The firm's CLI has the potential to detect cancer in real-time during surgery, and thereby reduce the need for repeat operations. The company was founded by David Tuch in 2012 and is headquartered in Chesham, the United Kingdom.

HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France.

LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France.

Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz.